Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 151 to 200 of 571

TitleReference numberPublishedLast updated
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatmentsTA852
Esketamine nasal spray for treatment-resistant depressionTA854
Cemiplimab for untreated PD-L1-positive advanced or metastatic non-small-cell lung cancer (terminated appraisal)TA848
Mepolizumab for treating eosinophilic granulomatosis with polyangiitis (terminated appraisal)TA845
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal)TA846
Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal)TA847
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal)TA843
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal)TA844
Subarachnoid haemorrhage caused by a ruptured aneurysm: diagnosis and managementNG228
Fractures (complex): assessment and managementNG37
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies (terminated appraisal)TA842
Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids (terminated appraisal)TA840
Advocacy services for adults with health and social care needsNG227
Slow-release potassium bicarbonate–potassium citrate for treating distal renal tubular acidosis (terminated appraisal)TA838
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA836
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Osteoarthritis in over 16s: diagnosis and managementNG226
Zanubrutinib for treating Waldenstrom's macroglobulinaemiaTA833
Fostamatinib for treating refractory chronic immune thrombocytopeniaTA835
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroidsTA832
Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapyTA827
Ozanimod for treating moderately to severely active ulcerative colitisTA828
Upadacitinib for treating active ankylosing spondylitisTA829
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Vedolizumab for treating chronic refractory pouchitis after surgery for ulcerative colitis (terminated appraisal)TA826
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Self-harm: assessment, management and preventing recurrenceNG225
Brolucizumab for treating diabetic macular oedemaTA820
Avalglucosidase alfa for treating Pompe diseaseTA821
Type 1 diabetes in adults: diagnosis and managementNG17
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsAMR2
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsAMR1
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitisTA814
Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancerTA812
Melanoma: assessment and managementNG14
Urinary tract infection in under 16s: diagnosis and managementNG224
Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia after 2 or more treatments (terminated appraisal)TA811
Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney diseaseTA809
Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrenceTA810

Results per page

  1. 10
  2. 25
  3. 50
  4. All